# A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

> **NCT05663515** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 24000 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Exenatide
- **DRUG:** Non-GLP-1 RA based glucose lowering drugs

## Key facts

- **NCT ID:** NCT05663515
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 24000 (ESTIMATED)
- **Last updated:** 2026-05-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05663515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05663515, "A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05663515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*